CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 374 enrolled
Drug / intervention
RO5185426drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01248936
NCT01248936Phase 2Completed
CompareCT.gov

A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA

Hoffmann-La Roche·interventional·Posted Nov 25, 2010·Updated Aug 12, 2016

In Brief

A Phase 2 clinical trial evaluating RO5185426 for Malignant Melanoma. Completed, enrolled 374 participants across 28 sites.

Detailed Summary

This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2010
Enrollment StartDec 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.6 years ago

Interventions

RO5185426drug